Papadopoulos Panayiota, Bousette Nicolas, Al-Ramli Wisam, You Zhipeng, Behm David J, Ohlstein Eliot H, Harrison Stephen M, Douglas Stephen A, Giaid Adel
Division of Cardiology, Montreal General Hospital, McGill University Health Center, Montreal, Que., Canada.
Atherosclerosis. 2009 Jun;204(2):395-404. doi: 10.1016/j.atherosclerosis.2008.10.044. Epub 2008 Nov 21.
Urotensin II (UII) and its receptor UT are upregulated in the pathological setting of various cardiovascular diseases including atherosclerosis. However, their exact role in atherosclerosis remains to be determined. In the present study we used four strains of mice; wild-type (WT), UT(+) (a transgenic strain expressing human UT driven by the alpha-smooth muscle-specific, SM22, promoter), ApoE knockout (ko), and UT(+)/ApoE ko. All animals were fed high fat diet for 12 weeks. Western blot analysis revealed a significant increase in aortic UT expression in UT(+) relative to WT mice (P<0.05). Aortas of ApoE ko mice expressed comparable UT protein level to that of UT(+). Immunohistochemistry revealed the presence of strong expression of UT and UII proteins in the atheroma of UT(+), ApoE ko and UT(+)/ApoE ko mice, particularly in foam cells. Serum cholesterol and triglyceride levels were significantly increased in ApoE ko and in UT(+)/ApoE ko but not in UT(+) mice when compared to WT mice (P<0.0001). Analysis of aortas showed a significant increase in atherosclerotic lesion in the UT(+), ApoE ko and UT(+)/ApoE ko compared to WT mice (P<0.05). Oral administration of the UT receptor antagonist SB-657510A (30 microg/Kg/day gavage) for 10 weeks in a group of ApoE ko mice fed on high fat diet resulted in a significant reduction of lesion (P<0.001). SB-657510A also significantly reduced ACAT-1 protein expression in the atherosclerotic lesion of ApoE ko mice (P<0.05). The present findings demonstrate an important role for UT in the pathogenesis of atherosclerosis. The use of UT receptor antagonists may provide a beneficial tool in the management of this debilitating disease process.
尾加压素 II(UII)及其受体 UT 在包括动脉粥样硬化在内的各种心血管疾病的病理情况下会上调。然而,它们在动脉粥样硬化中的确切作用仍有待确定。在本研究中,我们使用了四种小鼠品系:野生型(WT)、UT(+)(一种由α平滑肌特异性启动子 SM22 驱动表达人 UT 的转基因品系)、载脂蛋白 E 基因敲除(ko)小鼠以及 UT(+)/ApoE ko 小鼠。所有动物均喂食高脂饮食 12 周。蛋白质印迹分析显示,与 WT 小鼠相比,UT(+)小鼠主动脉中 UT 表达显著增加(P<0.05)。ApoE ko 小鼠主动脉中 UT 蛋白水平与 UT(+)小鼠相当。免疫组织化学显示,UT(+)、ApoE ko 和 UT(+)/ApoE ko 小鼠动脉粥样硬化斑块中存在强烈的 UT 和 UII 蛋白表达,尤其是在泡沫细胞中。与 WT 小鼠相比,ApoE ko 和 UT(+)/ApoE ko 小鼠的血清胆固醇和甘油三酯水平显著升高,但 UT(+)小鼠未升高(P<0.0001)。主动脉分析显示,与 WT 小鼠相比,UT(+)、ApoE ko 和 UT(+)/ApoE ko 小鼠的动脉粥样硬化病变显著增加(P<0.05)。在一组喂食高脂饮食的 ApoE ko 小鼠中,口服 UT 受体拮抗剂 SB - 657510A(30 微克/千克/天灌胃)10 周导致病变显著减少(P<0.001)。SB - 657510A 还显著降低了 ApoE ko 小鼠动脉粥样硬化病变中 ACAT - 1 蛋白的表达(P<0.05)。本研究结果表明 UT 在动脉粥样硬化发病机制中起重要作用。使用 UT 受体拮抗剂可能为管理这种使人衰弱的疾病过程提供一种有益的手段。